
Moderna’s mRNA Flu Vaccine Wins Unanimous FDA Panel Backing
FDA’s independent advisory committee unanimously backs Moderna’s new mRNA flu vaccine, mFlusiva, citing benefits outweigh risks. Final decision expected in August could offer better protection for older adults against mutating flu strains.










